| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10591277 | Bioorganic & Medicinal Chemistry Letters | 2013 | 6 Pages |
Abstract
The design and improvement of a novel series of muscarinic M3 receptor antagonists is described, leading to the identification of AZD8683, which was selected for clinical evaluation as a potential treatment for COPD.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Antonio Mete, Keith Bowers, Richard J. Bull, Helen Coope, David K. Donald, Katherine J. Escott, Rhonan Ford, Ken Grime, Andrew Mather, Nicholas C. Ray, Vince Russell,